Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide.
Fair value with moderate growth potential.
Share Price & News
How has Teva Pharmaceutical Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TEVA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: TEVA underperformed the US Pharmaceuticals industry which returned 6.7% over the past year.
Return vs Market: TEVA underperformed the US Market which returned 20.1% over the past year.
Price Volatility Vs. Market
How volatile is Teva Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StCan We See Significant Institutional Ownership On The Teva Pharmaceutical Industries Limited (NYSE:TEVA) Share Register?
2 months ago | Simply Wall StSome Teva Pharmaceutical Industries (NYSE:TEVA) Shareholders Have Taken A Painful 83% Share Price Drop
3 months ago | Simply Wall StTeva Pharmaceutical Industries Limited Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Is Teva Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TEVA ($12.22) is trading below our estimate of fair value ($27.55)
Significantly Below Fair Value: TEVA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TEVA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: TEVA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TEVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TEVA is good value based on its PB Ratio (1x) compared to the US Pharmaceuticals industry average (3x).
How is Teva Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TEVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: TEVA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TEVA's is expected to become profitable in the next 3 years.
Revenue vs Market: TEVA's revenue (0.5% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: TEVA's revenue (0.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TEVA's Return on Equity is forecast to be low in 3 years time (16.8%).
How has Teva Pharmaceutical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TEVA is currently unprofitable.
Growing Profit Margin: TEVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TEVA is unprofitable, and losses have increased over the past 5 years at a rate of -46.7% per year.
Accelerating Growth: Unable to compare TEVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TEVA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).
Return on Equity
High ROE: TEVA has a negative Return on Equity (-6.65%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Teva Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: TEVA's short term assets ($13.6B) do not cover its short term liabilities ($13.8B).
Long Term Liabilities: TEVA's short term assets ($13.6B) do not cover its long term liabilities ($28.7B).
Debt to Equity History and Analysis
Debt Level: TEVA's debt to equity ratio (177.9%) is considered high.
Reducing Debt: TEVA's debt to equity ratio has increased from 44.3% to 177.9% over the past 5 years.
Inventory Level: TEVA has a low level of unsold assets or inventory.
Debt Coverage by Assets: TEVA's debt is not covered by short term assets (assets are 0.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable TEVA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: TEVA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -20.5% per year.
What is Teva Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate TEVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate TEVA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TEVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TEVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: TEVA is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TEVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kåre Schultz (58yo)
Mr. Kåre Schultz has been the Chief Executive Officer, President and Director of Teva Pharmaceutical Industries Limited since November 1, 2017. Mr. Schultz is a seasoned veteran in the healthcare industry ...
CEO Compensation Analysis
Compensation vs Market: Kåre's total compensation ($USD32.47M) is above average for companies of similar size in the US market ($USD10.78M).
Compensation vs Earnings: Kåre's compensation has increased whilst the company is unprofitable.
|Executive VP||1.1yrs||US$5.25m||0.0066% $880.8k|
|Executive Vice President of Global R&D||3yrs||US$5.98m||0.0031% $407.0k|
|Executive VP & CFO||0.2yrs||no data||no data|
|Executive Vice President of Global Operations||0.3yrs||no data||0.0019% $252.2k|
|Senior VP & Chief Accounting Officer||0yrs||no data||no data|
|Senior Vice President of Investor Relations||0yrs||no data||no data|
|Executive VP & Chief Legal Officer||3.3yrs||no data||0.00027% $36.0k|
|Senior VP & Global Compliance Officer||4.7yrs||no data||no data|
|Executive Vice President of Global Marketing & Portfolio||2.3yrs||no data||0.0016% $220.2k|
Experienced Management: TEVA's management team is considered experienced (2.3 years average tenure).
|Independent Director||2.6yrs||US$235.53k||no data|
|Independent Director||2.6yrs||US$245.71k||no data|
|Independent Chairman of the Board||3yrs||US$378.00k||0.020% $2.7m|
|Independent Director||11.1yrs||US$246.32k||0.18% $24.4m|
|Independent Director||4.4yrs||US$250.72k||0.00095% $126.8k|
|Independent Director||2.6yrs||US$241.43k||no data|
|Independent Director||5.7yrs||US$232.68k||0.00045% $60.1k|
|Independent Director||4.4yrs||US$235.00k||0.00099% $132.1k|
|Independent Director||2.6yrs||US$211.71k||no data|
Experienced Board: TEVA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.9%.
Teva Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources
- Name: Teva Pharmaceutical Industries Limited
- Ticker: TEVA
- Exchange: NYSE
- Founded: 1901
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$13.345b
- Shares outstanding: 1.09b
- Website: https://www.tevapharm.com
Number of Employees
- Teva Pharmaceutical Industries Limited
- 5 Basel Street
- Petach Tikva
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TEVA||NYSE (New York Stock Exchange)||Yes||ADR EACH CNV INTO 1 ORD||US||USD||Feb 1982|
|TEV||DB (Deutsche Boerse AG)||Yes||ADR EACH CNV INTO 1 ORD||DE||EUR||Feb 1982|
|TEVA N||BMV (Bolsa Mexicana de Valores)||Yes||ADR EACH CNV INTO 1 ORD||MX||MXN||Feb 1982|
|TEVA||SWX (SIX Swiss Exchange)||Yes||ADR EACH CNV INTO 1 ORD||CH||CHF||Feb 1982|
|0LER||LSE (London Stock Exchange)||Yes||ADR EACH CNV INTO 1 ORD||GB||USD||Feb 1982|
|TEVA||WBAG (Wiener Boerse AG)||Yes||ADR EACH CNV INTO 1 ORD||AT||EUR||Feb 1982|
|TEVJ.F||OTCPK (Pink Sheets LLC)||Ordinary Shares||US||USD||Jun 1994|
|TEVA||TASE (The Tel-Aviv Stock Exchange)||Ordinary Shares||IL||ILS||Jun 1994|
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 23:49|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.